ArticleJCSM communications
Non-Cirrhotic Steatotic Liver Disease is Associated With Impaired Muscle Function: A Cross-Sectional Study.
Article in JCSM communications. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06514300 (MYO-SLD), which is not on this map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
MYO-SLD : a Prospective Study to Determine the Phenotype of Muscle Fat Accumulation in a Cohort of Patients With SLD as to Confirm the Association Between Muscle Composition and Texture and the Phenotype of Liver Disease
Who cites it
3 citing papers in PubMed.
- Subcutaneous Fat Density Is an Independent Predictor of Adverse Outcomes and Shows Early Improvement After Liver Transplantation.Liver international : official journal of the International Association for the Study of the Liver · 2026Article
- Association between pretherapeutic M2BPGi levels and postoperative skeletal muscle depletion in patients with esophageal squamous cell carcinoma.Esophagus : official journal of the Japan Esophageal Society · 2026Article
- Non-Cirrhotic Steatotic Liver Disease is Associated With Impaired Muscle Function: A Cross-Sectional Study.JCSM communicationsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Background: Impaired muscle function is frequent in cirrhosis and potentially participates in liver disease progression. Data from non-cirrhotic patients with steatotic liver disease (SLD) are lacking. Our aims were to determine if muscle function was impaired in a non-cirrhotic cohort of patients with SLD and if the SLD subtype and severity were associated with impaired muscle function. Methods: Patients with SLD and controls were prospectively recruited. Liver disease was assessed by imaging, vibration-controlled transient elastography and non-invasive tests. Muscle function was assessed by the liver frailty index (LFI) and isokinetic dynamometer. Diet and physical activity habits were recorded using dedicated questionnaires to measure the energetic balance. Results: One-hundred and fifty patients with non-cirrhotic SLD (75 patients with metabolic dysfunction-associated steatotic liver disease [MASLD] and 75 patients with alcohol-related liver disease [ALD]) and 30 non-SLD controls were prospectively recruited. The LFI negatively correlated to lower limb muscle strength assessed by isokinetic dynamometer in all participant groups ( Conclusions: Patients with SLD already show impaired muscle function compared to controls independently of age, gender and energetic balance. Taken together, our data support a potential disruption of the liver-muscle axis already occurring in SLD prior to cirrhosis. Trial Registration: ClinicalTrials.gov identifier: NCT06514300.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.